Researchers calculated U.S. consumption patterns from 1909 to 1999 by following the availability of essential fatty acids in 373 food commodities over the course of that time.
Diets high in omega-6s and low in omega-3s have been linked to a variety of problems relating to inflammation. A recent study conducted at the NIH National Institute on Alcohol Abuse and Alcoholism, published by the American Journal of Clinical Nutrition, attempts to elucidate the United States shift towards a diet overwhelmingly high in omega-6s.
Researchers calculated U.S. consumption patterns from 1909 to 1999 by following the availability of essential fatty acids in 373 food commodities over the course of that time.
Consumption of soybean oil, which is high in omega-6s, is estimated to have increased 1,000-fold during the time frame.
Overall availability of omega-6 linoleic acid (LA) increased from 2.79% to 7.21% of energy in the diet while availability of omega-3 alpha-linolenic acid (ALA) increased from 0.39% to just 0.72%. LA to ALA ratios increased from 6.4 in 1909 to 10.0 in 1999.
The researchers concluded that significant increases in omega-6 foods, primarily from soybean oil, have likely resulted in significant decreases in tissue omega-3 levels.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.